2-甲基-2-疏基硫酸脲 | 2986-19-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硫脲
• 分子结构分类: 有机化合物 - 有机硫化合物 - 异硫脲类
• 中文名称: 2-甲基-2-疏基硫酸脲
• 英文名称: carbamimidothioic acid methyl ester
• 英文别名: S-methylisothiourea；methyl carbamimidothioate；2-methylisothiourea；(methylsulfanyl)methanimidamide；Carbamimidothioic acid, methyl ester
• CAS: 2986-19-8
• 化学式: C₂H₆N₂S
• mdl: MFCD00129752
• 分子量: 90.149
• InChiKey: SDDKIZNHOCEXTF-UHFFFAOYSA-N

物化性质

• 熔点：
  240-241 °C (dec.)(lit.)
• 沸点：
  138.8±23.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)
• 溶解度：
  在水中的溶解度0.1 g/mL，澄清，无色

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  5
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 危险品运输编号：
  UN 2811
• 海关编码：
  2930909090
• 安全说明：
  S22,S24/25
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P301+P310
• 危险性描述：
  H301

反应信息

• 作为反应物：
  描述：

  2-甲基-2-疏基硫酸脲 在 chlorophosphoric acid 作用下， 以 乙腈 为溶剂， 生成 [[amino(methylsulfanyl)methylidene]amino]phosphonic acid
  参考文献：
  名称：

  一类具有丹参酮IIA和磷酸肌酸复合结构化合物的制备及其在防止心血管类疾病的应用

  摘要：

  本发明公开了具有丹参酮IIA和磷酸肌酸复合结构类化合物，其制备及其在医药上的应用。具体而言，本发明涉及一种通式(I)所示的新的化合物及其可药用的盐(钠盐，钾盐等)或含有其的药物组合物，及其制备方法。本发明还公开了所述化合物及其可药用的盐或含有其的药物组合物防治心血管类相关疾病的疾病预防和临床治疗的应用。其中通式(I)的结构说明同说明书中的定义相同。

  公开号：

  CN109485690A
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 甲醇 、 sodium methylate 作用下， 生成 2-甲基-2-疏基硫酸脲
  参考文献：
  名称：

  Characteristics of the response of ovine granulocytes (PMNs) to zymosan-activated serum (ZAS) and to recombinant human interleukin-8 (IL-8)

  摘要：

  The chemotactic activity of zymosan‐activated serum (ZAS) and of two concentrations of recombinant human IL‐8 (IL‐825, 25 ng/ml; IL‐850, 50 ng/ml) for ovine polymorphonuclear granulocytes (PMNs) was tested in a modified Boyden chamber. Thick cellulose acetate filters and the leading front method were used to quantify the movements of the cells. Both ZAS and IL‐825 exerted a chemotactic effect on ovine PMNs (P < 0.01): IL‐850 induced a more homogeneous response (P < 0.001). To verify the characteristics of the responsiveness to the chemokines after short‐term (st) or long‐term (lt) repeated samplings, chemotaxis was investigated 1 (T1st), 2 (T2st), 24 (T3st) and 48 h (T4st) after the basal sampling (T0st) and 15 days (T1lt) after the basal sampling (T0lt). No differences in chemotaxis were found in long‐term repeated samplings. In contrast an increase in the responsiveness to IL‐825 and to IL‐850 (P < 0.05) was detected at T2st in comparison with T0st. Furthermore, the significance of the distance run by activated PMNs compared with the controls, increased from T0st to T2st, as a sign of a more homogeneous response to the chemokines. In the absence of evident changes in circulating leucocyte numbers and in serum cortisol concentrations, these findings could be interpreted as a consequence of a different expression of chemoattractant receptors on the membrane of PMNs collected at different times.

  DOI：

  10.1046/j.1439-0442.2000.00303.x
• 作为试剂：
  描述：

  6-acetyl-3-cyano-7-(2-dimethylaminovinyl)pyrazolo<1,5-a>pyrimidine 在 sodium acetate 、 2-甲基-2-疏基硫酸脲 、 溶剂黄146 作用下， 生成 6-hydroxypyrazolo[1,5-a]quinazoline 3-carbonitrile 、
  参考文献：
  名称：

  Bruni; Costanzo; Selleri, Il Farmaco, 1993, vol. 48, # 2, p. 309 - 319

  摘要：

  DOI：

文献信息

• Discovery of Highly Potent 2-Sulfonyl-Pyrimidinyl Derivatives for Apoptosis Inhibition and Ischemia Treatment
  作者：Li Li、Xian Jiang、Shaoqiang Huang、Zhengxin Ying、Zhaolan Zhang、Chenjie Pan、Sisi Li、Xiaodong Wang、Zhiyuan Zhang

  DOI：10.1021/acsmedchemlett.6b00489

  日期：2017.4.13

  series of 2-sulfonyl-pyrimidinyl derivatives was developed as apoptosis inhibitors. These represent the first class of apoptosis inhibitors that function through stabilizing mitochondrial respiratory complex II. Starting from a phenotypic screen hit with micromolar activity, we optimized the cellular apoptosis inhibition activity of 2-sulfonyl-pyrimidinyl derivatives to picomolar level (compound 42

  开发了一系列2-磺酰基-嘧啶基衍生物作为凋亡抑制剂。这些代表通过稳定线粒体呼吸复合物II起作用的第一类凋亡抑制剂。从具有微摩尔活性的表型筛选开始，我们将2-磺酰基-嘧啶基衍生物的细胞凋亡抑制活性优化至皮摩尔水平（化合物42，也称为TC9-305）。这些新的细胞凋亡抑制剂对缺血动物模型的神经保护作用进一步证明了其治疗潜力。
• Pyridopyrimidinones derivatives as telomerase inhibitors
  申请人：Pharmacia Italia S.p.A.

  公开号：US20040009993A1

  公开（公告）日：2004-01-15

  The invention provides novel pyrido[2,3-d]pyrimidin-7(8H)-ones derivatives active as telomerase inhibitors, the use of the derivatives as therapeutic agents, such as antitumoral agents, processes for preparation of the derivatives, and to pharmaceutical compositions comprising the derivatives.

  这项发明提供了作为端粒酶抑制剂活性的新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物，以及这些衍生物作为治疗剂（如抗肿瘤剂）的用途，制备这些衍生物的方法，以及包含这些衍生物的药物组合物。
• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047959A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量、空腹血糖升高、2型糖尿病、综合征X（也称为代谢综合征）及其相关疾病和并发症。
• PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190047961A1

  公开（公告）日：2019-02-14

  The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

  本发明涉及吡啶-2-酮衍生物，包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用，用于治疗例如受损的口服葡萄糖耐量，空腹血糖升高，2型糖尿病，综合征X（也称为代谢综合征）以及与之相关的疾病和并发症。
• [EN] BROAD-SPECTRUM CARBAPENEMS<br/>[FR] CARBAPÉNÈMES À LARGE SPECTRE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2019232053A1

  公开（公告）日：2019-12-05

  The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.

  本公开提供广谱碳青霉烯衍生物及用于治疗细菌感染的药物组合物，以及使用这些衍生物和/或组合物治疗感染的方法。